Navigation Links
Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
Date:9/23/2010

t to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.  

ABBOTT PARK, Ill. and IRVING, Texas, Sept. 23 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD).  

Under terms of the agreement, Reata will grant to Abbott exclusive rights to develop and commercialize bardoxolone outside the U.S., excluding certain Asian markets.  Reata will receive upfront and near-term cash payments of $450 million for the licensing rights to bardoxolone and a minority equity investment in the company.  Upon completion of certain development and approval objectives for bardoxolone and other molecules in the licensed territories, Reata will receive additional milestone payments.  Reata also will receive royalties on any future product sales in the Abbott territories.  Additionally, Abbott obtains rights to develop and commercialize certain other Reata compounds for chronic kidney disease, and for cardiovascular and metabolic indications, in these territories.

"Early clinical studies suggest that bardoxolone could be a significant improvement to the current standard of care for CKD and possibly prevent patients from progressing to the later stages of the disease and dialysis," said John Leonard, M.D., senior vice president, pharmaceuticals, research and development, Abbott.  "This agreement builds on Abbott's existing experience in renal care, while adding a promising compound to our later-stage pipeline."

Bardoxolone is an oral, first-in-class antioxidant inflammation modulator that works by increasing the estimated glomerular filtration rate (eGFR) of the kidneys.
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- On Thursday, July 10, 2014, ... Jones Industrial Average finished the day 0.42% lower at 16,915.07, ... losses were broad based as eight out of ten sectors ... Sector Index ended the day at 711.88, down 0.02%, while ... Investor-Edge has initiated coverage on the following equities: Covidien PLC ...
(Date:7/11/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) has ... Testing Market - Forecasts to 2019: Expected to ... is expected to be valued at USD 4,943.0 ... http://photos.prnewswire.com/prnh/20130307/600769 The ... according to immunoprotein types which include immunoglobulins, complement ...
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... Ill., April 11, 2011 Hospira, Inc. (NYSE: ... company, today announced that the company will present at the ... on Wednesday, May 11, 2011, in Las Vegas. ... time on Wednesday, May 11, 2011.  It will be available ...
... PharMEDium Healthcare Corporation has become an Industry Supporter ... part of a new Corporate Supporter program available to ... David N. Jonas, PharMEDium Chairman and CEO commented, "We ... anesthesiology field through leadership, education and research.  As a ...
Cached Medicine Technology:PharMEDium Becomes a Corporate Supporter of the American Society of Anesthesiologists (ASA) 2
(Date:7/13/2014)... The report “Micronutrient Market by Type (Zinc, Manganese, ... Chelated), Application Mode (Soil, Foliar, Fertigation), Crop Type ... 2018” defines and segments the global agriculture micronutrients ... global value and volume for agriculture micronutrients. It ... the global agriculture micronutrients market with an analysis ...
(Date:7/13/2014)... According to a new market research ... Component (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), ... - Forecast and Analysis to 2014-2020", published by ... Market is expected to reach $61.70 Billion by ... 2014 to 2020. , Browse 71 market data ...
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July ... sensor for people with diabetes is being developed to measure ... researchers report. Scientists at Brown University in Providence, R.I., ... It uses light, metal and a special enzyme that changes ... diabetics have to prick their fingers to draw blood to ...
(Date:7/13/2014)... New York (PRWEB) July 13, 2014 ... ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson & ... second bellwether trial, which is expected to get underway ... issued in the U.S. District Court, Southern District of ... will be held on August 7, 2014 at 3:00 ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular suppliers ... released its new range of elegant Quinceanera dresses ... at discounted prices. Worldwide clients can enjoy this special ... company’s online shop, there are plenty of beautiful dresses ... great materials. MyDressCity.com’s hot items are prom gowns, bridesmaid ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2
... for bowel cancer based upon a molecule found only in ... curable if caught early. Screening with sigmoidoscopy - an internal ... disease. Now researchers in the find that a reliable test ... ,The bowel sheds cells into feces all the time. The ...
... The West Indian Cherry or Acerola fruit (Malpighia Punicifolia ... to man. Hundred grams of edible portion yields 1000 ... Cherry tree grows well in the tropical parts in ... is rich in Vitamin A, potassium, calcium, phosphorus and ...
... results from a study of a new drug for ... delivered intravenously every three weeks, was found to be ... is one of a group of drugs called chloroethylnitrosoureas. ... been shown to help shrink solid tumors, including cancerous ...
... middle-aged mice which shows that a low-cal diet keeps the ... extending the lifespan// - and this has been found in ... low-cal diet prevents the genetic changes that signal the aging ... used 'gene chip' technology to analyse thousands of genes active ...
... Ireland, Boston and the Netherlands, it was confirmed that ... the air really can save lives. The investigators in Dublin ... coal in Dublin. They studied the death rates in the ... the ban, the amount of black smoke decreased by about ...
... seafood at least once a week have a reduced risk of ... 1205 people aged over 65 //and without dementia at the beginning. ... seafood, then followed them up to, five and seven years afterwards. ... a week had a significantly lower risk of being diagnosed with ...
Cached Medicine News:
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 6.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 12 mm....
Medicine Products: